Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Polpharma Simplifies Structure By Absorbing Subsidiaries

As Company Works To Achieve Operational Efficiency

Executive Summary

Poland’s Polpharma SA has absorbed subsidiaries Polpharma BH and Medana Pharma as part of the group’s efforts to simplify management structures and processes and increase operational efficiency.

You may also be interested in...



Deal Watch: Artios Links Up With Novartis On DNA Damage Response Modifiers

Oncology partnership with Swiss major follows late 2020 pact with Merck KGaA. Pfizer divests Phase Ib breast cancer candidate to Celcuity.

Polpharma Biologics Rebrands As New Warsaw Site Is Validated

As it gears up to begin production at its new clinical and commercial manufacturing site in Warsaw, Polpharma Biologics has announced a new logo and corporate message to mark a year of “significant growth.”

Polpharma Biologics Integrates Bioceros

Polpharma Biologics is making strategic moves to become a truly integrated CDMO by bringing its Dutch Bioceros subsidiary under the Polpharma Biologics brand.

Related Content

Topics

UsernamePublicRestriction

Register

GB150811

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel